icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Substantial
Substantial in the treatment of SJIA.
Clinical Added Value
moderate
Like ROACTEMRA (tocilizumab), ILARIS (canakinumab) provides a moderate improvement in actual benefit (level III) in the management of patients aged 2 years and older, with active systemic juvenile idiopathic arthritis, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids.
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
yJ6Z8Q9THDqBeDSG